Today (12/21) the U.S. Food and Drug Administration (FDA) approved the first oral treatment for prostate cancer, a disease that affects on average one in every nine men. Orgovyx, created by Myovant, was created to treat advanced prostate cancer cases by blocking the pituitary gland in the brain from creating testosterone, ultimately causing medical castration. The drug comes at a particularly appealing time for prostate cancer patients, as it reduces the clinic visits during the global pandemic.
Read more here.
More on: News Regulatory